Center-Authored Papers

Filters: Author is Alumkal, Joshi J  [Clear All Filters]
Journal Article
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R et al..  2016.  Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.. Oncotarget. 7(26):40690-40703. Abstract
Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung D et al..  2017.  Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.. Clinical genitourinary cancer. Abstract
Geybels MS, Alumkal JJ, Luedeke M, Rinckleb A, Zhao S, Shui IM, Bibikova M, Klotzle B, van den Brandt PA, Ostrander EA et al..  2015.  Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.. Clinical epigenetics. 7:128. Abstract
Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D et al..  2011.  A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.. Science translational medicine. 3(85):85ra47. Abstract
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R et al..  2016.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.. European urology. Abstract
Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM et al..  2017.  Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.. European journal of cancer (Oxford, England : 1990). Abstract